Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus
Rev. Assoc. Med. Bras. (1992, Impr.)
;
44(4): 289-93, out.-dez. 1998. ilus
Artigo
em Inglês
| LILACS
| ID: lil-220909
RESUMO
Objective. To evaluate the efficacy of long-term thalidomide treatment in cutaneous lesions os systemic lupus erythematosus (SLE), not responsive to conventional therapy. Patients and Methods. Were selected 18 SLE patients (ACR criteria) with active cutaneous lesions not responsive to chloroquine, photoprotectors and low doses prednisone and who presented good response to thalidomide but relapsed after withdrawal of the drug. All female patients had no risk of pregnancy. Thalidomide was reintroduced and maintained at low dose (25-100 mg/day) for a minimum of 6 months. Results. Eighteen patients (16 females) with mean age of 34.2yo (16-57y.o.) received thalidomide for 6-21 months (mean 8.5m). The mean dose of prednisone at beginning of study was 38.3 mg/d and at the end was 9.7 mg/d (p<0.05). Complete remission of cutaneous lesions was observed in thirteen patients (72 per cent) and partial remission in five (28 per cent). Side effects observed were drowsiness in eight patients, intestinal constipation in 5, transient oliguria in 1, paresthesia of hand with normal electromyography in another one. All side effects disappeared with reduction of thalidomide dose and no patient needed to stop treatment owing to side effect. Conclusion. Thalidomide is a good alternative therapy to SLE patients with refractory cutaneous lesions and without any risk of pregnancy.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Talidomida
/
Prednisona
/
Imunossupressores
/
Lúpus Eritematoso Sistêmico
Limite:
Adolescente
/
Adulto
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Rev. Assoc. Med. Bras. (1992, Impr.)
Assunto da revista:
EducaÆo em Sa£de
/
GestÆo do Conhecimento para a Pesquisa em Sa£de
/
Medicina
Ano de publicação:
1998
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS